Cramer: Valeant fuss a ‘travesty’
The situation surrounding Valeant Pharmaceuticals has transformed the company into a "great mystery," CNBC's Jim Cramer said Monday. "The numbers ...
The situation surrounding Valeant Pharmaceuticals has transformed the company into a "great mystery," CNBC's Jim Cramer said Monday. "The numbers ...
Shares of Valeant Pharmaceuticals tumbled on Tuesday after the company cut its 2016 revenue forecast by about 12 percent and ...
Not even Valeant's turbulent fourth quarter could hold back Viking Global in 2015. Ole Andreas Halvorsen's Viking Global Equities fund ...